The incidence and significance of pattern-recognition receptors in chronic viral hepatitis types B and C in man.
Chronic viral hepatitis B and C are among the most common and devastating liver diseases worldwide. Immune response plays a crucial role in the course of both diseases. In spite of the importance of the adaptive arm of the immune response, there is a growing role of innate immunity, the earliest confronted with viral attack. Pattern-recognition receptors (PRRs) and, in particular, Toll-like receptors (TLRs) are molecules which are able not only to recognize foreign invaders, but also quickly mount an antiviral defense. Activation of PRRs has been demonstrated in both hepatitis types, i.e. in situ in the liver and on while blood cells. Both viruses, HCV and HBV, are able to subvert the PRR-mediated antiviral response by means of various proteins and enzymes. HCV acts via the non-structural proteins NS2 and NS3/4A, while HBV HBeAg is inversely correlated with TLR activity. Viral counterattack is particularly directed toward dendritic cells, those creating the link with the adaptive immune response. Apart from TLRs, other PRRs such as RIG-1 and MDA-5 are also able to recognize viral infection and participate in the activation of type I interferon synthesis. TLRs manifest gene polymorphism, which was shown to affect several consequences associated with chronic viral hepatitis such as liver cirrhosis and the outcome of liver allotransplantation. There have been numerous attempts to take advantage of the existence and activity of PRRs for the patients' benefit. Several authors examined the role of TLR synthetic agonists as inducers of TLR activation. In hepatitis C the most promising agonists appear to be TLR3, 7, and 9 for potential antiviral therapy. PRRs may also act as potent adjuvants in HBV vaccines. Their baseline mRNA levels may have predictive value in the course of antiviral therapy.
Department of Infectious Diseases, University of Medical Sciences, Poznan, Poland.
Iwona
I
Mozer-Lisewska
Jan
J
Sikora
Arleta
A
Kowala-Piaskowska
Mariusz
M
Kaczmarek
Grzegorz
G
Dworacki
Jan
J
Zeromski
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D015703:Antigens, CD / Q000276:immunology; D000998:Antiviral Agents / Q000276:immunology / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate / Q000276:immunology; D008099:Liver / Q000166:cytology / Q000276:immunology / Q000821:virology; D011110:Polymorphism, Genetic; D051192:Receptors, Pattern Recognition / Q000235:genetics / Q000276:immunology*; D051193:Toll-Like Receptors / Q000235:genetics / Q000276:immunology
D000276:Adjuvants, Immunologic; D015703:Antigens, CD; D000998:Antiviral Agents; D051192:Receptors, Pattern Recognition; D051193:Toll-Like Receptors